Maternal RSV Vaccines and Infant Shots Offer Equal Aid
A new study shows both methods provide similar, high-level protection for newborns against RSV-related infections.
Updated on Oct. 28, 2026 in Babies
Live Poll
Do you prefer relying on your own research to choose medical preventions for your newborn?
A new observational study finds that both maternal vaccination during pregnancy and infant antibody shots offer comparable protection against RSV. Researchers tracked over 15,000 full-term infants across two RSV seasons to compare these two primary preventative options.
Why it matters
For expectant parents choosing how to protect newborns from RSV, this study indicates that both clinical options provide significant, similar benefits in reducing severe infection and hospitalization risks. The findings help clarify the relative effectiveness of these two widely available preventative measures.
The maternal vaccine, given at 32 to 36 weeks of pregnancy, was associated with an 86.4% reduction in hospitalizations, while the nirsevimab shot administered in the first week of life reduced them by 73.8% compared to no protection. Total hospitalizations across both groups were 12.
The players
JAMA Network Open
A peer-reviewed medical journal that published the observational study results.
National Institute of Allergy and Infectious Diseases
A federal agency that funds research into preventing and treating infectious diseases.
Kaiser Permanente Division of Research
A health system research department that contributed to the study design and analysis.
The details
Researchers matched infants by birth week, sex, and various maternal factors to compare outcomes for babies aged 8 to 180 days. The maternal vaccine works by transferring protective antibodies to the fetus during pregnancy, whereas nirsevimab provides direct immune support to the newborn shortly after birth. Both methods were evaluated against a baseline of no preventative protection during the 2023-24 and 2024-25 RSV seasons.
Timeline
2023-24 RSV season: data collection period for study infants.
2024-25 RSV season: data collection period for study infants.
October 24, 2026: study results published and presented at IDWeek.
The Home Front
This research provides clinical context to the rapidly evolving landscape of pediatric RSV prevention policies. It sits alongside recent regulatory shifts that have expanded access to both maternal vaccination and infant monoclonal antibody treatments for families nationwide.
If you are currently pregnant or expecting, discuss these two preventative options with your OB-GYN or pediatrician to determine which timing and delivery method best fits your family. Keep your medical records updated with any immunizations or antibody treatments your infant receives.
The takeaway
Both maternal RSV vaccination and infant nirsevimab injections offer effective, similar protection for newborns. Parents should prioritize a conversation with their healthcare provider during pregnancy to plan for these preventative health steps before the RSV season begins.
Further reading
For more on keeping newborns healthy, visit our Babies section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you prefer relying on your own research to choose medical preventions for your newborn?
